Despite zero revenue and increased losses, Capricor Therapeutics Inc (CAPR) focuses on strategic initiatives and regulatory ...

Type A meeting with U.S. FDA scheduled to discuss Deramiocel BLA and path toward potential approvalCapricor seeks to resubmit ...

Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration ...

The law firm of Kirby McInerney LLP reminds investors who purchased Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR) securities to contact Thomas W. Elrod of Kirby McInerney LLP ...

Capricor Therapeutics Inc.‘s board overhyped regulatory approval odds for its cell therapy to treat a serious heart condition, leading to a series of stock drops, a shareholder lawsuit said.

Participants can use guest dial-in numbers above and be answered by an operator or click the Call me™ link for instant telephone access to the event. Webcast: Webcast Link - Click Here A replay ...

Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...

Replimune (NASDAQ:REPL), and Capricor Therapeutics (NASDAQ:CAPR), which faced regulatory setbacks from the FDA’s biologics ...

Capricor Therapeutics, Inc. (CAPR) is scheduled to announce Q2 earnings results on Wednesday, August 13th, after market close. The consensus EPS Estimate is -$0 ...

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases.

Capricor Therapeutics announced that it will release its financial results for the first quarter of 2025 on May 13, 2025, after market close, followed by a conference call and webcast at 4:30 p.m. ET.